Sedana Medical AB (publ), Third Quarter Report 2021
Sedaconda (isoflurane) approved in 11 European marketsThird quarter 2021 · Net sales totalled SEK 28 M (21), equivalent to an increase of 32% compared to the third quarter of 2020. At constant exchange rates, sales increased by 34% with all regions showing positive growth. · Gross profit was SEK 19 M (13), equivalent to a margin of 68% (62). The improved margin is primarily an effect of lower transportation costs, favorable product mix and timing effects. · Earnings before interest, taxes, depreciation, and amortisation (EBITDA) totalled SEK -14 M (-10), equivalent to an EBITDA